Braidwell »

Celldex Therapeutics shares owned by Braidwell

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Braidwell from 13F filings

Historical chart of Braidwell investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Braidwell consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Braidwell

Quarter filed Position value Share count Share price at filing
2025-09-30 $15M 592k 25.87

More positions owned by Braidwell

Guardant Health Debt 1.250% 2/1 (Principal)
Caris Life Sciences (CAI)
Novocure Note 11/0 (Principal)
Xenon Pharmaceuticals (XENE)
Cg Oncology (CGON)
Neurocrine Biosciences (NBIX)
Repligen Corp Note 1.000%12/1 (Principal)
Krystal Biotech (KRYS)
Nuvalent Inc-a (NUVL)
Neogenomics Note 0.250% 1/1 (Principal)
Soleno Therapeutics (SLNO)
Irhythm Technologies Note 1.500% 9/0 (Principal)
Edgewise Therapeutics (EWTX)
Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal)
Inspire Med Sys (INSP)

View all positions for Braidwell

Top funds holding Celldex Therapeutics

Kynam Capital Management
Wellington Management Company
BlackRock
FMR
Vanguard Group
Point72 Asset Management
Bellevue Group
Commodore Capital
State Street Corporation
Deep Track Capital
Eventide Asset Management
Geode Capital Management
Polar Capital Holdings
Pictet Asset Management Holding SA
Vestal Point Capital

View all funds holding Celldex Therapeutics